Published in World J Gastroenterol on January 07, 2010
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol (2011) 0.83
Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis (2001) 1.28
Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther (2003) 1.25
A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol (2003) 1.20
Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut (2000) 1.17
Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther (2003) 0.97
Colorectal transport in normal defaecation. Colorectal Dis (2003) 0.88
Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun? World J Gastroenterol (2009) 0.86
A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol). Aliment Pharmacol Ther (2009) 0.83
Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: pathophysiology and clinical associations. Inflamm Bowel Dis (2014) 2.00
A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem (2008) 1.10
The grand challenge of birth control. Science (2004) 1.09
Synthesis and identification of small molecules that potently induce apoptosis in melanoma cells through G1 cell cycle arrest. J Am Chem Soc (2005) 1.00
The effects of a higher protein intake during energy restriction on changes in body composition and physical function in older women. J Gerontol A Biol Sci Med Sci (2011) 0.95
Types of colitis based on histology. Dis Mon (2011) 0.92
Relationship between mesenteric abnormalities on computed tomography and malignancy: clinical findings and outcomes of 359 patients. J Clin Gastroenterol (2013) 0.91
Clinical and endoscopic features of angiosarcoma of the colon: two case reports and a review of the literature. J Gastrointest Cancer (2013) 0.87
Calcium phosphate nephropathy from colonoscopy preparations: effect of body weight. Am J Gastroenterol (2010) 0.87
Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis (2013) 0.86
Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol (2013) 0.84
Effects of protein intake and gender on body composition changes: a randomized clinical weight loss trial. Nutr Metab (Lond) (2012) 0.83
Identification from a combinatorial library of a small molecule that selectively induces apoptosis in cancer cells. J Am Chem Soc (2003) 0.82
Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature. Ann Pharmacother (2013) 0.82
Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. J Am Acad Dermatol (2013) 0.82
A colorimetric substrate for poly(ADP-ribose) polymerase-1, VPARP, and tankyrase-1. Angew Chem Int Ed Engl (2007) 0.81
Accuracy and reliability of the endoscopic classification of chronic radiation-induced proctopathy using a novel grading method. J Clin Gastroenterol (2005) 0.79
Emerging treatments for irritable bowel syndrome. Expert Opin Pharmacother (2002) 0.79
Alvimopan (Adolor/GlaxoSmithKline). Curr Opin Investig Drugs (2002) 0.79
Constipation. Dis Mon (2011) 0.79
Diarrhea. Dis Mon (2011) 0.78
Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System. Drug Saf (2013) 0.77
Inpatient Costs for Patients with Inflammatory Bowel Disease and Acute Pancreatitis. Inflamm Bowel Dis (2016) 0.77
Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case. Dis Colon Rectum (2003) 0.76
Increased poly(ADP-ribose) polymerase activity during porcine hemorrhagic shock is transient and predictive of mortality. Resuscitation (2007) 0.75
Lower body weight and female gender: hyperphosphatemia risk factors after sodium phosphate preparations. World J Gastroenterol (2011) 0.75
Other effects on the colon. Dis Mon (2011) 0.75
Attitudes and Usage of the Food and Drug Administration Adverse Event Reporting System Among Gastroenterology Nurse Practitioners and Physician Assistants. Gastroenterol Nurs (2016) 0.75
Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System. Eur J Clin Pharmacol (2012) 0.75
A computer simulation of the prevention of the transmission of Toxoplasma gondii on swine farms using a feline T. gondii vaccine. Prev Vet Med (2002) 0.75
Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis. Inflamm Bowel Dis (2013) 0.75
Method for the current review. Dis Mon (2011) 0.75
Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis. J Clin Gastroenterol (2015) 0.75